

# YOU ARE INVITED

## Gilead Sciences invites you to a ZYDELIG® (idelalisib) educational event

### Zydelig: A Case Study Review

#### Meeting Overview

- Review key details of FDA-approved ZYDELIG Prescribing Information
- Present design of key trials, efficacy profile, and safety profile
- Learn more about dosing and dose modifications

No CME credit is offered

#### Presented by:

**David Rizzieri, MD**  
Professor of Medicine  
Duke University Medical Center

#### Date:

**Friday, April 27th, 2018**  
**1:00 PM – 2:30 PM**  
Eastern Standard Time

#### Location:

**The Conrad Hilton Hotel Miami**  
1395 Brickell Avenue  
Miami, FL 33131  
305-503-6585

#### Registration:

**Pre-meeting registration is not required for this meeting.**

Please be aware that if you are a licensed US physician, any meal associated with this program is reportable under the Federal Open Payments/Sunshine Act. Gilead policy and the PhRMA Code on Interactions with Healthcare Professionals limit attendance at this promotional educational program to healthcare professionals. Accordingly, attendance by guests is not appropriate and cannot be accommodated.

Please see accompanying full Prescribing Information, including **BOXED WARNING** regarding fatal and serious toxicities of hepatotoxicity, severe diarrhea/colitis, pneumonitis, infections, and intestinal perforation.



©2018 Gilead Sciences, Inc. All rights reserved. ZYDP0505 02/2018  
Gilead, the Gilead logo, ZYDELIG, and the ZYDELIG logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies.

